Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P179
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Brahmer, Julie
Balmanoukian, Ani
Goldberg, Sarah
Ou, Sai-Hong
Blake-Haskins, Andrew
Karakunnel, Joyson
Stockman, Paul
Rizvi, Naiyer
Antonia, Scott
Article History
First Online: 6 November 2014